U.S. migraine patients with a prescription may now buy innovative medical device
After much anticipation, CEFALY Technology announced today that the Cefaly medical device for the preventative treatment for migraine headaches is available for purchase and delivery in the United States for patients with a medical prescription at Cefaly. The Cefaly medical device received U.S. Food and Drug Administration (FDA) approval for thepreventative treatment for migraine headaches on March 11, 2014. It is the first transcutaneous electrical nerve stimulation device specifically authorized for use prior to the onset of pain.
“The emails and phone calls asking where to purchase Cefaly have been non-stop since we announced the device would be made available in the United States,” said Doctor Pierre Rigaux, the chief executive officer of CEFALY Technology, the Belgian maker and member of the inventors team of the Cefaly . “I’m very happy to let migraineurs in the U.S. know that Cefaly is now ready for U.S. purchase for patients with a prescription.”
Cefaly is a battery-powered device that resembles a headband and is affixed to the center of the forehead using a self-adhesive electrode that applies an electric current to the skin and underlying body tissues to stimulate branches of the trigeminal nerve, which has been associated with migraine headaches. Cefaly is available by prescription-only and indicated for patients 18 years of age and older. It should only be used once daily for 20 minutes. Women who are pregnant or could become pregnant should check with their doctor before using Cefaly.
Cefaly costs $295 plus $29 shipping and handling. The electrodes needed to operate the device cost $25 for a set of three (each electrode will last for up to approximately 20-uses). There is a 60-day money back guarantee.
The company that manufactures Cefaly expects to make the device available via select pharmacies and clinics in the months ahead.
Cefaly is also available in Canada and Europe.
For more information, visit CEFALY Technology.
